Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

NCT01217437 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

NIH

Sponsor class

Conditions

Central Nervous System Neoplasm
Pineoblastoma
Recurrent Medulloblastoma
Recurrent Primitive Neuroectodermal Tumor
Refractory Medulloblastoma
Refractory Peripheral Primitive Neuroectodermal Tumor

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Irinotecan Hydrochloride
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)